Iovance Biotherapeutics (2LB) Stock Overview
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
2LB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Iovance Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.47 |
| 52 Week High | US$4.74 |
| 52 Week Low | US$1.43 |
| Beta | 0.70 |
| 1 Month Change | 1.32% |
| 3 Month Change | 19.77% |
| 1 Year Change | 134.66% |
| 3 Year Change | -46.23% |
| 5 Year Change | -83.73% |
| Change since IPO | -72.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2LB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.2% | 2.7% | 1.7% |
| 1Y | 134.7% | -5.8% | 2.6% |
Return vs Industry: 2LB exceeded the German Biotechs industry which returned -5.7% over the past year.
Return vs Market: 2LB exceeded the German Market which returned 1.1% over the past year.
Price Volatility
| 2LB volatility | |
|---|---|
| 2LB Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 2LB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2LB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 975 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.
Iovance Biotherapeutics, Inc. Fundamentals Summary
| 2LB fundamental statistics | |
|---|---|
| Market cap | €1.55b |
| Earnings (TTM) | -€309.59m |
| Revenue (TTM) | €249.88m |
Is 2LB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2LB income statement (TTM) | |
|---|---|
| Revenue | US$285.61m |
| Cost of Revenue | US$172.97m |
| Gross Profit | US$112.64m |
| Other Expenses | US$466.50m |
| Earnings | -US$353.86m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 39.44% |
| Net Profit Margin | -123.90% |
| Debt/Equity Ratio | 0.1% |
How did 2LB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 06:09 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Iovance Biotherapeutics, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Madhu Kumar | Baird |
| Peter Lawson | Barclays |